2-amino-4-phosphonobutyric acid has been researched along with Parkinson Disease in 3 studies
2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Austin, PJ | 1 |
Betts, MJ | 1 |
Broadstock, M | 1 |
O'Neill, MJ | 1 |
Mitchell, SN | 1 |
Duty, S | 1 |
Valenti, O | 1 |
Marino, MJ | 1 |
Wittmann, M | 1 |
Lis, E | 1 |
DiLella, AG | 1 |
Kinney, GG | 1 |
Conn, PJ | 1 |
Vernon, AC | 1 |
Croucher, MJ | 1 |
Dexter, DT | 1 |
3 other studies available for 2-amino-4-phosphonobutyric acid and Parkinson Disease
Article | Year |
---|---|
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Aspartic Acid; Disease Models, Animal; Excitatory Amino Acid Agonists; Glut | 2010 |
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.
Topics: Adrenergic Uptake Inhibitors; Aminobutyrates; Animals; Corpus Striatum; Disease Models, Animal; Elec | 2003 |
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
Topics: Aminobutyrates; Animals; Brain; Cytoprotection; Disease Models, Animal; Drug Therapy, Combination; E | 2008 |